Jim Cramer says he likes these 5 Nasdaq stocks for 2023

Jim Cramer says he likes these 5 Nasdaq stocks for 2023


Cramer explains why many of the stocks listed in the Nasdaq Composite don't fit his investing rubric

CNBC’s Jim Cramer on Thursday gave investors a list of stocks that he believes could be worthwhile additions to investors’ portfolios.

All of his picks are listed in the Nasdaq Composite. While the index is heavy with tech stocks that were hammered last year, there are still names that could perform well even in a recessionary environment, according to Cramer.

“In an index that’s been folded, spindled and mutilated, I am still feeling good about a few of these stocks,” he said.

Here are his picks:

T-Mobile

  • Cramer said that he expects the company to continue taking market share from competitors.

Regeneron Pharmaceuticals

  • “Regeneron’s got a broad pipeline with a ridiculously cheap stock. I think it’s a really, really excellent situation, especially if you’re expecting a severe recession,” he said.

PepsiCo

  • The beverage giant rivals Procter & Gamble when it comes to the best consumer packaged goods company in the U.S., he said, though he acknowledged that the stock’s valuation is a bit higher than he would like.

American Electric Power

  • Cramer said that he likes the stock because the company is well-run, and utility stocks tend to perform well during economic slowdowns.

Dollar Tree

  • While he does like the stock compared to other retailers listed on the Nasdaq, Cramer said that he still prefers TJX Companies.

Disclaimer: Cramer’s Charitable Trust owns shares of TJX Companies.

Jim Cramer says he likes these 5 Nasdaq stocks

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says
Business

More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says

More than 20,000 people have started taking Eli Lilly‘s GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly’s once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk’s Wegovy pill. Investors have been closely tracking […]

Read More
Lawyers to the wealthy warn that AI legal advice comes with serious risks
Business

Lawyers to the wealthy warn that AI legal advice comes with serious risks

Displeased couple having problems during a meeting with their agent in the office. Skynesher | E+ | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Lawyer Tasha Dickinson said […]

Read More
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Business

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past […]

Read More